Mosquito, zika

As Disease Creeps North, Zika Screening Test Development Accelerates

By MedTech Intelligence Staff
No Comments
Mosquito, zika

APRIL FOOL’S: Part of this article is true, but we made up some stuff along the way. Read on to find out where.

–UPDATE — 4/1/2016; 16:49 pm — This article was part of our April Fool’s edition. 13% of poll participants guessed that this story was fake. It looks like many of you didn’t read hard enough. A 3-D printed device for use in Brazil? A portable breath test? Not as far as we know. We made that stuff up. The Roche screening test, however, is indeed a real development.

Experts are predicting that the Zika virus will steadily continue to climb its way north, especially as the summer season approaches in the northern hemisphere. In anticipation, several companies and research institutions are working to develop solutions to rapidly screen for the virus.

Earlier this week FDA announced the availability of a screening test for blood donations, provided by Roche, (to be used under an investigational new drug application) in areas that have reported transmission of the Zika virus. This will allow locations that have stopped collecting donations to resume, including Puerto Rico, which reportedly imported almost 6000 units of blood from the continental United States over fears of contamination.

And here’s the April Foolery:

Other Zika screening tests currently in development include a 3-D printed device (the microfluidics are 3-D printed) intended for point-of-care use in clinics in Brazil; and a non-invasive, portable breath test, which has the potential to be used on-site in remote regions where healthcare is not readily accessible. “Although there is a push to develop rapid blood screening tests for Zika, having the ability to provide clinicians, and even non-healthcare professionals, access to a test that they can use immediately will provide far more value in ensuring early treatment of this disease,” said Gerard Velam, M.D., research fellow at the Institute of Infectious Disease in Brazil.

Related Articles

  • MilliporeSigma and Erbi Logos

    The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.

  • Tim Brown

    Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.

  • Avania and MAXIS logos

    The acquisition brings MAXIS’ expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management to Avania’s contract research and MedTech development capabilities.

  • Veranex logo

    The acquisition expands Veranex’s European footprint as well as the scale and scope of its clinical studies capabilities.

Leave a Reply

Your email address will not be published. Required fields are marked *